A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

To join this study, you need to be between 12 and 75 years old. You should have had eczema for at least three years if you're an adult, or at least one year if you're under 18. Your eczema needs to be moderate to severe, covering at least 10% of your body, and causing significant itchiness.

It's important that your current eczema treatment, such as creams, hasn't been working well enough for at least six months, or you haven't been able to use them for other reasons. You'll also need to be using moisturiser regularly before and during the study.

You wouldn't be able to join if your eczema is getting rapidly better or worse, or if you have other skin conditions that might make it hard to tell if the new medicine is working. People with other serious health problems affecting major body systems could also be excluded.

If you decide to take part in this study, you would first go through a screening process to make sure you meet all the requirements. If you qualify, you'd be in the study for a total of about 68 weeks. The first 16 weeks involve regular visits to the clinic, where you might receive either the study medicine (KT-621) or a dummy medicine (placebo). Neither you nor the study team will know which you are receiving during this period. After these initial 16 weeks, all eligible participants will have the opportunity to take KT-621 for another 52 weeks.

During your visits, you'll have check-ups, blood tests, and we'll ask you questions about your eczema and how you're feeling. You'll also be asked to keep a record of your symptoms and how itchy you are using an electronic diary. All participants will take the study medicine by mouth, and you'll need to follow specific instructions on how and when to take it. There will be planned follow-up appointments and assessments throughout the study timeline.